We reasoned that our CDK12NULL patients could represent the previously reported fraction of breast cancer patients harboring CDK12 loss-of-function mutations, a condition also described in other cancers, including ovarian and prostate cancer, and associated with aggressive disease course10,12,29–31. This evidence concerns the gene CDK12 and prostate cancer.